Letters to the Editor
Low Omicron BA.4 and BA.5 neutralising activity and breakthrough COVID-19 following pre-exposure prophylaxis with tixagevimab plus cilgavimab in vaccinated patients with autoimmune disease
C.M. Connolly1, A.H. Karaba2, T. Po-Yu chiang3, M. Teles4, J.D. Kim5, T. Scott Johnson6, J.L. Alejo7, D.L. Segev8, L. Christopher-Stine9, W.A. Werbel10, J.J. Paik11
- Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Department of Surgery, NYU Grossman School of Medicine, New York, NY, USA.
- Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jpaik1@jhmi.edu
CER16443
2023 Vol.41, N°5
PI 1202, PF 1203
Letters to the Editor
Free to view
(click on article PDF icon to read the article)
PMID: 36826787 [PubMed]
Received: 08/12/2022
Accepted : 16/01/2023
In Press: 23/02/2023
Published: 03/05/2023